Childhood absence epilepsy is a genetic neurological disorder that usually begins in children between the ages of 4 to 10 years. It is characterized by brief periods of staring spells associated with altered level of consciousness and minor twitching or jerking of body parts. Drugs available for treatment of childhood absence epilepsy are ethosuximide, valproate, and lamotrigine. These drugs help control seizures by stabilizing abnormal electrical activity in the brain during seizures.

Market key trends:

The childhood absence epilepsy treatment market is primarily driven by increasing number of research and development activities by key players. For instance, in January 2020, Takeda Pharmaceutical Company Limited announced positive top-line results from Phase 3 study (ELEKTRA trial) evaluating the efficacy and safety of the investigational drug,lacosamide as adjunctive therapy in pediatric patients aged 2-16 years with JME (juvenile myoclonic epilepsy) or CAE (childhood absence epilepsy). Such increased R&D focus by prominent players is expected to result in development of more effective treatment alternatives, thereby propelling market growth over the forecast period.

Porter’s Analysis

Threat of new entrants: Low capital requirements and established brand loyalty makes it difficult for new players to enter the market.

Bargaining power of buyers: Large patient pool makes individual customers have low bargaining power. Switching costs are also relatively low.

Bargaining power of suppliers: The presence of few suppliers and established buyer-supplier relationships gives suppliers moderate bargaining power.

Threat of new substitutes: Potential substitutes with improved efficacy pose a low to moderate threat due to patent protection of available drugs.

Competitive rivalry: The market is highly competitive with Jazz Pharmaceuticals, Inc. being the dominant player focusing on expanding indications.

SWOT Analysis
Strength: Established drugs with proven efficacy and safety. Strong R&D capabilities and resources to invest in clinical development.
Weakness: High dependency on key drugs and indications. Potential pipeline failures could impact future growth.
Opportunity: High unmet needs in developing countries present commercialization opportunities. Favorable regulatory policies to spur innovation.
Threats: Price controls and market access hurdles across regions. Increasing generic competition on mature products.

Key Takeaways

The Global Childhood Absence Epilepsy Treatment Market Size is expected to witness high growth, exhibiting CAGR of 7.4% over the forecast period, due to increasing awareness about epilepsy and availability of treatment options.

Regional analysis North America currently dominates the global market and is estimated to witness a CAGR of 6.9% during the forecast period. This is attributed to well-established healthcare infrastructure and availability of advanced treatment & screening facilities in the region. Meanwhile, Asia Pacific is expected to emerge as the fastest growing regional market during the forecast period, exhibiting a CAGR of around 8.6%. This is driven by rising prevalence of the condition combined with improving accessibility to diagnosis & care.

For More Insights, Read- https://www.feedsfloor.com/pharmaceuticals/childhood-absence-epilepsy-treatment-market-estimated-witness-high-growth-owing